Sodium-Glucose Co-Transporter 2 Inhibitors and the Risk of Venous Thromboembolism in Patients with Type 2 Diabetes: A Cohort Study.

Abstract

PURPOSE:

We assessed whether sodium-glucose co-transporter type 2 (SGLT2) inhibitors are associated with a higher incidence rate of venous thromboembolism in patients with type 2 diabetes.

METHODS:

We conducted a population-based cohort study using the InGef database including patients with type 2 diabetes newly treated with noninsulin antidiabetic drugs between 2012 and 2018. Cases of venous thromboembolism identified during follow-up were matched to 40 controls on age, sex, cohort entry date, and duration of follow-up. Using a nested case-control approach, conditional logistic regression estimated incidence rate ratios (RRs) with 95% confidence intervals (CIs) of venous thromboembolism adjusted for sociodemographic and clinical variables, comparing current use of SGLT2 inhibitors with current use of dipeptidyl peptidase-4 (DPP-4) inhibitors.

RESULTS:

In a cohort of 219,538 patients, we identified 2152 cases of venous thromboembolism and matched them to 85,104 controls. Compared with DPP-4 inhibitors, current use of SGLT2 inhibitors was associated with a lower rate of venous thromboembolism (RR, 0.75; 95% CI, 0.59-0.94). Effect estimates were similar for dapagliflozin (RR, 0.77; 95% CI, 0.57-1.03) and empagliflozin (RR, 0.71; 95% CI, 0.52-0.98).

CONCLUSIONS:

Compared with DPP-4 inhibitors, SGLT2 inhibitors were not associated with a higher rate of venous thromboembolism, providing reassurance regarding their thromboembolic safety.

• Authors: Niklas Schmedt, Dirk Enders, Jochen Walker, Edeltraut Garbe, Antonios Douros
• Journal: The American journal of medicine (Am J Med) Vol. 134 Issue 5 Pg. 606-613.e6 (05 2021) ISSN: 1555-7162 [Electronic] United States
• PMID: 33316246 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2020 Elsevier Inc. All rights reserved.

Chemical References

• Sodium-Glucose Transporter 2 Inhibitors

Topics

• Aged
• Case-Control Studies
• Diabetes Mellitus, Type 2 (drug therapy)
• Female
• Humans
• Logistic Models
• Male
• Sodium-Glucose Transporter 2 Inhibitors (adverse effects, therapeutic use)
• Venous Thromboembolism (chemically induced)